Oppenheimer analyst Jay Olson maintains $Revolution Medicines (RVMD.US)$ with a buy rating, and adjusts the target price from $55 to $60.
According to TipRanks data, the analyst has a success rate of 39.0% and a total average return of 12.9% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Revolution Medicines (RVMD.US)$'s main analysts recently are as follows:
The initial Phase 1 data from RMC-9805 in patients with advanced pancreatic ductal adenocarcinoma presented at the EORTC-NCI-AACR Symposium bolstered the outlook for the ongoing second-line PDAC Phase 3 study of RMC-6036. The updated Phase 1/1b data that was shared last week has increased confidence in the potential success of the study.
Following recent clinical updates on '6236 and '9805 in PDAC, and an investor event, there is a positive outlook on the potential of '6236 in second line or later PDAC treatment, as the latest Phase 1 data indicated an enhanced median overall survival. Furthermore, initial data from the first-in-human trials of '9805 in PDAC has shown promising signs of clinical efficacy and an acceptable safety profile, exceeding initial expectations.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
奧本海默控股分析師Jay Olson維持$Revolution Medicines (RVMD.US)$買入評級，並將目標價從55美元上調至60美元。
根據TipRanks數據顯示，該分析師近一年總勝率為39.0%，總平均回報率為12.9%。
此外，綜合報道，$Revolution Medicines (RVMD.US)$近期主要分析師觀點如下：
在 EORTC-NCI-AACR 研討會上公佈的 RMC-9805 針對晚期胰腺導管腺癌患者的初始 1 期數據增強了正在進行的 RMC-6036 二線 PDAC 3 期研究的前景。上週分享的最新10/10期數據增強了人們對該研究潛在成功的信心。
繼最近PDAC中'6236和'9805的臨床更新以及一次投資者活動之後，由於最新的1期數據顯示總存活率中位數有所提高，人們對'6236在二線或以後的PDAC治療中的潛力持樂觀態度。此外，在PDAC中進行'9805的首次人體試驗的初步數據顯示出令人鼓舞的臨床療效跡象和可接受的安全性，超出了最初的預期。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
